Results 311 to 320 of about 2,542,870 (405)

Practical Applications of Secondary/Extractive Electrospray Ionization (SESI): A Versatile Tool for Real‐Time Chemical Analysis

Mass Spectrometry Reviews, EarlyView.
ABSTRACT In the 1980s, researchers discovered the remarkable ability of electrospray plumes to effectively ionize gas‐phase molecules via secondary ionization. Around 20 years later—coinciding with the ambient mass spectrometry revolution—secondary electrospray ionization (SESI) and extractive electrospray ionization (EESI) coupled to mass spectrometry
Xin Luo, Huiling Wang, Xiaolan Hu, Sasho Gligorovski, Xue Li, Pablo Sinues   +5 more
wiley   +1 more source

Inhibitory effects of the selective μ-opioid receptor antagonist UD-030 on methamphetamine-induced conditioned place preference. [PDF]

Neuropsychopharmacol Rep
Ide S, Iwase N, Arai K, Kojima M, Ushiyama S, Ikeda K.   +5 more
europepmc   +1 more source

Abolition of morphine-immunosuppression in mice lacking the μ-opioid receptor gene

, 1998
Claire Gavériaux‐Ruff, Hans W. D. Matthes, Jean Peluso, Brigitte L. Kieffer   +3 more
openalex   +1 more source

Restless Legs Syndrome and Impulsive Decision‐Making: Impact of Symptom Severity, Chronotype and Interoception

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Restless Legs Syndrome (RLS) is a neurological disorder reported to be associated with impulsivity and impairments in interoception and emotional regulation. However, limited research has explored the combined influence of RLS severity, psychological factors, and chronotype on impulsive decision‐making and risk‐taking behavior in ...
Giacomo Carollo, Riccardo Quinci, Gloria Pompea Mingolla, Angela Sandri, Michele Tinazzi, Elena Antelmi   +5 more
wiley   +1 more source

Mu-Opioid Receptor (MOR) Dependence of Pain in Chemotherapy-Induced Peripheral Neuropathy. [PDF]

J Neurosci
Araldi D, Staurengo-Ferrari L, Bogen O, Bonet IJM, Green PG, Levine JD.   +5 more
europepmc   +1 more source

Targeting Histone H3K9 Methyltransferase G9a as a Potential Therapeutic Strategy for Neuropsychiatric Disorders

Medicinal Research Reviews, EarlyView.
ABSTRACT Neuropsychiatric disorders present a multifaceted challenge, characterized by cognitive, social, and motor impairments with manifold underlying mechanisms. Recent attention has turned to epigenetic mechanisms, particularly histone lysine methyltransferases (HKMTs), such as G9a, in understanding fundamental pathogenesis.
Malak Hajar, Tobias Werner, Mihajlo Gajic, Holger Stark, Bassem Sadek   +4 more
wiley   +1 more source

The μ-opioid receptor is necessary for [d-Pen2,d-Pen5]enkephalin-induced analgesia

, 1997
Ichiro Sora, Masahiko Funada, George R. Uhl   +2 more
openalex   +1 more source

Pain Experiences and Prescription Pain Medications Among People With Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Pain is a recognized symptom of muscular dystrophy (MD), but little is known about prescription pain medications in this population. We describe pain experiences and pain medications prescribed for individuals with selected MDs using population‐based surveillance data collected by the Muscular Dystrophy Surveillance, Tracking,
Jonathan Suhl, Kristin M. Conway, Shiny Thomas, Sonja A. Rasmussen, James F. Howard, Nicholas E. Johnson, Paul A. Romitti, Katherine D. Mathews, The Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet)   +9 more
wiley   +1 more source

Navacaprant, a Novel and Highly Selective Kappa Opioid Receptor Antagonist, in Adults With Major Depressive Disorder: A Randomized, Double-Blind Phase 2 Clinical Trial. [PDF]

J Clin Psychopharmacol
Mathew SJ, Cutler AJ, Visitacion NC, Gold M, Yuan J, Aurora B.   +5 more
europepmc   +1 more source

Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

Obesity, EarlyView.
Abstract Background Glucagon‐like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP‐1s) are shifting the treatment landscape for obesity. However, real‐world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP‐1 efficacy, equitable results, and ...
Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa Sannidhi, Fatima Cody Stanford, Emily A. Callahan   +17 more
wiley   +1 more source